Drug Trial Radar · NCT04570839
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Aug 31, 2020
Primary completion
May 15, 2024
Study completion May 15, 2024
Sponsor
- Lead sponsor
- Compugen LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Sep 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM701 in combination with BMS-986207 and nivolumab in patients with advanced solid tumors.
Conditions
- Endometrial Neoplasms
- Ovarian Cancer
- Solid Tumor
- Head and Neck Cancer
Interventions
COM701 in combination with BMS-986207 and nivolumab.Drug
Study treatment with the 3 drug combination (COM701 in combination with BMS-986207 and nivolumab).
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects with adverse events on the study.Time frame: 2 years.
- The proportion of subjects with adverse events in the 1st cycle during dose escalation within the DLT window (28 days).Time frame: Within the DLT window (1st 28 days) of the 1st cycle during dose escalation.
- The recommended dose for expansion (RDFE) of the combination.Time frame: 2 years.
- The Area under the curve of COM701 in subjects receiving the 3-drug combination.Time frame: 2 years.
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of Chicago Medical Center
Chicago, Illinois
Johns Hopkins University Oncology Center.
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
START Midwest.
Grand Rapids, Michigan
Columbia University
New York, New York
University of Pittsburgh Cancer Center.
Pittsburgh, Pennsylvania
The University of Tennessee WEST Cancer Center.
Memphis, Tennessee
MD Anderson Cancer Center
Houston, Texas
The START Center for Cancer Care.
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.